Drug Profile
CS 0777
Alternative Names: CS-0777Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class
- Mechanism of Action Immunosuppressants; Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
- Discontinued Immunosuppression
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (PO, Tablet)
- 27 May 2014 Discontinued - Phase-I for Immunosuppression in European Union (PO)
- 27 May 2014 Discontinued - Phase-I for Immunosuppression in USA (PO)